Neuren Pharma (NEU) is held by 24 ASX ETFs. Over the last year it fell 4.8%: on $10,000, −$480. We explain 2 big moves in that time.
About NEU
- SectorHealth Care
- IndustryPharmaceuticals, Biotechnology & Life Sciences
- Size$2.6b
- Held by24 ETFs
- Big moves2 in 1Y
Last year−4.8%
$20.43−4.80% price
Each dot is a move we explain. Tap one, or a row of Why it moved, to see what caused it.
1Y high$23.64
1Y low$11.28
Avg volume440k
Latest volume213k
Prices to 5 Oct closePrice only, distributions not included
Why it moved
2 moves
- +16.9%5 Aug 2026· Sector Flow
NEU.AX rose sharply alongside a broad lift in Australian healthcare sector stocks, likely driven by positive sector-wide sentiment or macro tailwinds benefiting health equities that day.
- +36.1%29 Jun 2026· Regulatory
European regulator CHMP backed approval of Neuren's flagship drug Daybue, triggering a US$35m milestone payment and sending the stock up 35-36%.
Held by 24 ETFs
Of every $10,000 in each fund, how much is in NEU today.
- SMLLBetaShares Australian Small Companies Select ETF$2152.15%
- SSOSTATE STREET SPDR S&P/ASX SMALL ORDINARIES ETF$880.88%
- ISOiShares S&P/ASX Small Ordinaries ETF$870.87%
- QHSMVanEck MSCI International Small Companies Quality (AUD Hedged) ETF$600.60%
- QSMLVanEck MSCI International Small Companies Quality ETF$580.58%
- FAIRBetaShares Australian Sustainability Leaders ETF$480.48%
- ROYLBetaShares Global Royalties ETF$470.47%
- GRPAGlobal X S&P Australia GARP ETF$420.42%
- VSOVanguard MSCI Australian Small Companies Index ETF$380.38%
- AECVBETASHARES AUSTRALIAN SHARES CATHOLIC VALUES ETF$320.32%